Skip to main content
. 2021 Jan 10;13(1):84. doi: 10.3390/pharmaceutics13010084

Figure 7.

Figure 7

Survival curves (MTT assay) of triple negative breast cancer cell lines MDA-MB-231 (A) and MDA-MB-231PAC10 (B) with increasing concentrations of paclitaxel (PAC) and DDC-Cu (n = 3 ± SD). (C) The IC50 values of PAC and DDC-Cu on both breast cancer cell lines (n = 3 ± SD).